Rapid molecular detection of rifampicin resistance facilitates early diagnosis and treatment of multi-drug resistant tuberculosis: Case control study

PLoS ONE

Volumn 3, Issue 9, 2008, Pages

  O'Riordan, Philly ^a   Schwab, Uli ^a   Logan, Sarah ^a   Cooke, Graham ^a,b,e   Wilkinson, Robert J ^a,b,c   Davidson, Robert N ^a   Bassett, Paul ^a   Wall, Robert ^a   Pasvol, Geoffrey ^a,b   Flanagan, Katie L ^a,d  

^a NORTHWICK PARK HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^e UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; RNA POLYMERASE; STREPTOMYCIN; RNA POLYMERASE II; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; INTERMETHOD COMPARISON; LUNG SURGERY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; TUBERCULOSIS; DISEASE TRANSMISSION; GENETICS; MUTATION; RETROSPECTIVE STUDY; RISK; TREATMENT OUTCOME;

BACILLI (CLASS);

ANTIBIOTICS, ANTITUBERCULAR; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MUTATION; RETROSPECTIVE STUDIES; RIFAMPIN; RISK; RISK FACTORS; RNA POLYMERASE II; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 52649112761     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0003173     Document Type: Article

References (23)

1. Health Protection Agency, London (2006) Focus on Tuberculosis: Annual surveillance report 2006 - England, Wales and Northern Ireland. Available: http://www.hpa.org.uk/publications/2006/tb_report/ focus_on_tb.pdf. Accessed 2006 Nov.
2. World Health Organisation (2003) Treatment of Tuberculosis: Guidelines for National Programmes. Third Edition. Available: http://whqlibdoc.who.int/hq/2003/WHO_CDS_TB_2003.313_eng.pdf.2003.
3. Health Protection Agency, London (2005) The UK Mycobacterial Surveillance Network Report, 1994-2003. 10 years of MycobNet. Available: http://www.hpa.org.uk/infections/topics_az/th/pdf/ MycobNet_10_Year_Report.pdf. Accessed 2005 Dec.
4. Aziz M, Wright A, Laszlo A, De Muynck A, Portaels F, Van Deun A, Wells C, Nunn P, Blanc L, Raviglione MC (2006) Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet 368: 2142-2154.
5. Callister MEJ, Barringer J, Thanabalasingam ST, Gair R, Davidson RN (2002) Pulmonary tuberculosis among political asylum seekers screened at Heathrow Airport, London, 1995-9. Thorax 57(2): 152-156.
6. Drobniewski F, Eltringham I, Graham C, Magee JM, Smith EG, Watt B (2002) A national study or clinical and laboratory factors affecting the survival of patients with multiple drug resistant tuberculosis in the UK Thorax 57: 810-816.
7. Drobniewski F, Caws M (2001) Molecular techniques in the diagnosis of Mycobacterium tuberculosis and the detection of drug resistance. Ann NY Acad Sci 953: 138-45.
8. Watterson S, Wilson S, Yates M, Drobniewski F (1998) Comparison of three molecular assays for rapid detection of rifampicin resistance in Mycobacterium tuberculosis. J Clin Microbiol 36(7): 1969-73.
9. Sam I-C, Drobniewski F, More P, Kemp M, Brown T (2006) Mycobacterium Tuberculosis and Rifampicin Resistance, United Kingdom. Emerg Infect Dis 12(5): 752-759.
10. De Beenhouwer H, Liang Z, De Rijk P, Van Eekeren C, Portaels F (1995) Detection and identification of mycobacteria. by DNA amplification and oligonucleotide-specific capture plate hybridization. J Clin Microbiol 33(11): 2994-8.
11. El Sahly HM, Teeter LD, Pawlak RR, Musser JM, Graviss EA (2005) Drug-resistent tuberculosis: A disease of target populations in Houston, Texas. J Infect 53(1): 5-11.
12. Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370(9596): 1453-1457.
13. Hayward A, Bennett D, Hertbert J (1996) Risk Factors for drug resistance in patients with tuberculosis in England and Wales 1993-4. Thorax Suppl 3: S31.
14. Faustini A, Hall AJ, Perucci CA (2006) Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax 61: 158-163.
15. Ormerod P (2001) The clinical management of the drug-resistant patient. Ann NY Acad Sci 953: 185-191.
16. Cohn DL, Bustreo F, Raviglione MC (1997) Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD Global Surveillance Project. International Union Against Tuberculosis and Lung Disease. Clin Infect Dis 24(Suppl 1): S121-30.
17. Espinal MA (2003) The global situation of MDR-TB. Tuberculosis (Edinb) 83(1-3): 44-51.
18. Hardie RM, Watson JM (1993) Screening migrants at risk of tuberculosis. Brit MedJ 307(6918): 1539-40.
19. Ormerod LP (1998) Is new immigrant screening for tuberculosis still worthwhile? J Infect Dis 37 (1): 39-40.
20. Rajbhandary SS, Marks SM, Bock NN, Di Perri G, Bonora S, Post FA, Willcox PA, Mathema B, Steyn LM, Shean K, Ramaswamy SV, Graviss EA, Shashkina E, Kreiswirth BN, Kaplan G, Piana A, Orru M, Masia MD, Sotgiu G, Muresu E, Maida A, Espinal MA (2004) Costs of patients hospitalized for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 8(8): 1012-6.
21. White VLC, Moore-Gillon J (2000) Resource implications of patients with multidrug resistant tuberculosis. Thorax 55: 962-963.
22. World Health Organisation. Molecular line probe assays for rapid screening of patients at risk of multi-drug resistant tuberculosis (MDR-TB). Expert Group Report. May 2008.
23. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman ME (2008) Rapid Molecular Screening for MDR-TB in a High Volume Public Health Laboratory in South Africa. Am J Respir Crit Care Med 177(7): 787-792.